Past Presenting Companies |
OneMedForum SF 2011 Presenting Companies
| Company | Description | Recent News |
 Adeona Pharmaceuticals, Inc. (AMEX: AEN) [Micro-Cap Biotech/Device] | Adeona Pharmaceuticals, Inc. is a company dedicated to the awareness, diagnosis, prevention and treatment of subclinical zinc deficiency and chronic copper toxicity in the mature population. Adeona believes that such conditions may contribute to the progression of debilitating degenerative diseases, including, >>> Video Profile | Adeona Acquires Access to Clinical Data Supporting Oral Zinc for Prevention of Infections in the Elderly Adeona CEO to Present at Medical Technology-Life Sciences Event |
 ADS Biotechnology, Ltd. (Private) [Private Biotech/Device] | ADS Biotechnology, Ltd. is an early stage biomedical company to pursue the commercial development of a novel, first-in-class blood volume expander created by three scientists at the University of Toledo's College of Medicine. | |
 Aduro Biotech (Private) [Private Biotech/Device] | Aduro Biotech, Inc.is developing non-invasive targeted therapeutics for the treatment of cancers. | Biotech Quest For Cash Continues
Aduro BioTech Announces Key Milestones in Advancing Its Leading Listeria Based Immunotherapy Program |
 Advanced Bifurcation Systems (Private) [Private Biotech/Device] | Advanced Bifurcation Systems is a medical device company focusing on technologies enabling and facilitating seamless stenting of all coronary bifurcation disease scenarios. ABS (Advanced Bifurcation Systems) approach is radically different from all other technologies currently in use or development. | |
 Advanced Cell Technology (OTC-BB: ACTC) [Micro-Cap Biotech/Device] | Advanced Cell Technology, Inc. is a biotechnology company that specializes in the development of cellular therapies for the treatment of rare and common diseases that impact millions of people worldwide. The company applies stem cell-based technologies and other proprietary methods in the area of regenerative medicine to bring patient-specific therapies from the lab to the bedside. >>> Video Profile | Advanced Cell Technology Receives FDA Clearance For Clinical Trials Using Embryonic Stem Cells to Treat Age-Related Macular Degeneration Advanced Cell Technology Secures $25 Million Funding Commitment |
 ADVENTRX Pharmaceuticals (NYSE AMEX: ANX) [Micro-Cap Biotech/Device] | ADVENTRX Pharmaceuticals is a development-stage specialty pharmaceutical company focused on acquiring, developing and commercializing proprietary product candidates for the treatment of cancer. >>> Video Profile | ADVENTRX Announces 12-Month Stability Data Results for ANX-530 ADVENTRX Pharmaceuticals to Present at The Rodman & Renshaw Annual Global Investment Conference on September 14 |
 AesRx (Private) [Private Biotech/Device] | AesRx is a biopharmaceutical company dedicated to the development of two novel drugs to treat sickle cell anemia and certain inflammatory diseases of the lower intestine, including distal ulcerative colitis, pouchitis and radiation induced proctitis. | Professor Henry Louis Gates, Jr., Joins AesRx Strategic Advisory Board
AesRx CEO Selected as Panelist for Georgetown Biotechnology Event |
 Alverix (Private) [Private Biotech/Device] | Alverix is a world leader in design and manufacturing of next generation instrument and connectivity platforms for diagnostic Point-of-Care (POC) testing. Alverix systems enable laboratory class performance in a mobile, inexpensive format, extending precision testing beyond high volume sites to physician office labs, retail clinics, emerging markets and the home. | Alverix CEO, Ric Tarbox, at AdvaMed 2010 Alverix Working with BD to Develop and Manufacture Next-Generation POC Systems |
 Apricus Bio (Nasdaq: APRI) [Micro-Cap Biotech/Device] | Backed by a solid, revenue generating CRO business, Bio-Quant, Inc. and its NexMed USA subsidiary, Apricus Bio has leveraged the flexibility of its proven NexACT® drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. >>> Video Profile | Apricus Biosciences Launches Educational Video Series Focused On Its Newly Approved Erectile Dysfunction
APRICUS BIOSCIENCES APPOINTS MANUFACTURER FOR VITAROS®, ITS NEWLY APPROVED DRUG TO TREAT ERECTILE DYSFUNCTION IN CANADA |
 Ascalon International (Private) [Private Biotech/Device] | Ascalon International Inc. is a privately-held oncology development company. The company is committed to developing products and achieving target positioning by well identified clinical development and regulatory execution, either by establishment of a joint development with the product owner or by more classical acquisition of the product. | Ascalon Leverages Experienced Management Team, Strategic Partnerships for Cancer Drug Development New Oncology Developer Ascalon International Inc. Announces Deal With CerRx Inc. |
 Bacterin International (OTCBB: BIHI) [Micro-Cap Biotech/Device] | Bacterin is a medical device company and accredited tissue bank that designs, processes, manufactures, and markets advanced medical products. Bacterin's Biologics Division has revolutionized the handling characteristics of allograft bone for transplantation. The Company's biologic scaffolds, OsteoSponge®, OsteoSponge® SC and OsteoWrap®, are made from demineralized human bone, highly malleable and flexible for efficient and precise handling, delivering an osteoinductive and osteoconductive interconnected porous matrix essential for supporting the patient's own stem cells and new bone formation. | Bacterin International Secures Up To $9 Million of Potential $14 Million of Financing Bacterin International Holdings, Inc. Reports Third Quarter 2010 Financial Results |
 BioCurex (OTC BB: BOCX.OB) [Micro-Cap Biotech/Device] | Biocurex is a biotechnology company focused on developing and commercializing products for early cancer diagnosis using a proprietary blood test based on the RECAF™ tumor marker. | BioCurex Cancer Monitoring Data Accepted for Presentation at International Scientific Meeting on Cancer Markers BioCurex Announces Positive First Results for Monitoring Cancer Therapy Using its RECAF Blood Test. |
 BioVest International (OTCPK: BVTI) [Micro-Cap Biotech/Device] | Biovest International is a majority-owned subsidiary of Accentia Biopharmaceuticals Inc., a vertically-integrated specialty biopharmaceutical company with services to commercialize targeted therapeutics. Accentia is a publicly traded company (NASDAQ: ABPI) that has a product portfolio featuring targeted therapeutics, specialty sales and marketing, pharmacoeconomic services, product development, and specialty distribution. | Positive, Clinically Significant Phase III Results for Personalized Anti-Cancer Vaccine, BiovaxID®, Presented at ASCO Plenary Session
|
 BioVigil (Private) [Private Biotech/Device] | The BioVigil BV-140 badge series uses an advanced metal oxide alcohol sensor to detect the presence of hand sanitizer on a user's hands. | BioVigil Improves Hygiene with Hospital Monitoring System New hand sanitation monitors at VCU Medical Center |
 Biovista, Inc. (Private) [Private Biotech/Device] | Biovista technology finds new uses for drugs and is used by the FDA to help predict AEs with a very high degree of accruacy. Biovista has developed programs in MS, epilepsy and oncology. Biovista is in collaboration with Pfizer to find new uses for certain Pfizer drugs. >>> Video Profile | Biovista Featured in CHI's InsightPharma Report on Drug Repositioning
Biovista Announces the Appointment of Clifford H. Farrah to its Advisory Board |
 Cambridge Heart (OTC BB: CAMH.OB.OB) [Micro-Cap Biotech/Device] | Cambridge Heart develops and markets products for the non-invasive diagnosis of cardiac disease. The company focuses specifically on the area of sudden cardiac arrest with proprietary technology capable of measuring Microvolt T-Wave Alternans (MTWA) which indicate variations in a patient's heartbeat. | Cambridge Heart Reports Results for the Three and Six Months Ended June 30, 2010
Cardiac Science Launches Cambridge Heart's Microvolt T-Wave Alternans (MTWA) Technology in Stress Test Systems |
 CardioInsight Technologies (Private) [Private Biotech/Device] | CardioInsight was formed to commercialize electrocardiographic imaging technology developed at Case Western University. The CardioInsight technology non-invasively images electrical activity on the surface of the heart. Proof of concept has been demonstrated in animal studies and preliminary human trials. | CardioInsight Technologies Closes $6 Million Funding Round |
 Cardium Therapeutics (AMEX: CXM) [Micro-Cap Biotech/Device] | Cardium is focused on the acquisition and strategic development of new and innovative biomedical product opportunities and businesses that have the potential to address significant unmet medical needs and definable pathways to partnering, commercialization and other economic monetizations >>> Video Profile | Cardium Awarded Grant Under Qualifying Therapeutic Discovery Project Program Cardium to Present at 10th Annual Biotech in Europe Investor Forum Cardium Announces Appexium™, a New Weight Loss Management Dietary Supplement to Expand MedPodium's Healthy Lifestyle Product Initiative |
 Castlewood Surgical (Private) [Private Biotech/Device] | Castlewood Surgical, Inc. is a medical device company that is committed to improving the care of patients with cardiovascular disease. Their mission is to leverage physician and engineering innovation to improve patient outcomes while operating an efficient business driving toward profitability. >>> Video Profile | Cyclone™ Device
|
 CeQur (Private) [Private Biotech/Device] | CeQur is an insulin delivery device company, developing and commercializing a small, discrete, and uniquely simple insulin delivery device for people with type 2 diabetes. >>> Video Profile | Massachusetts Medical Device Journal, January 2010: Q&A with CeQur CEO Jim Peterson Start Up magazine, January 2010: CeQur makes the "A-List" |
 Cervilenz Inc (Private) [Private Biotech/Device] | CerviLenz is an innovative tool that measures vaginal cervical length during pregnancy. CerviLenz is a low cost, single use, FDA cleared medical device manufactured and distributed by CerviLenz Inc. With CerviLenz, obstetricians, nurse-midwives, and L&D nurses can make confident decisions faster in preterm labor triage. | CerviLenz in the News |
 Claro Scientific (Private) [Private Biotech/Device] | Claro Scientific is an early-stage biomedical company that utilizes breakthroughs in biophotonic research to develop portable, low-cost devices to rapidly identify micro-organisms from bodily fluid samples, including blood, urine and saliva. | Claro Scientific to Present at Northeast Landmark Venture Forum Claro Scientific Awarded $245,000 in Grants under the Therapeutic Discovery Tax Credit Program |
 Compumedics (ASX: CMP) [Micro-Cap Biotech/Device] | Compumedics offers innovative computer based diagnostic technologies in the areas of Sleep, Neurology and Cardiology. >>> Video Profile | Compumedics DWL makes TCD Waves in Croatia Grael wins Powerhouse Museum award for design excellence and innovation |
 Curemark (Private) [Private Biotech/Device] | Curemark is a pioneering, research-driven biotechnology company that develops and markets innovative products to fulfill needs in neurological medicine. Curemark is focused on the treatment of neurological and other diseases by addressing certain pancreatic secretory deficiencies. | Curemark Featured in Business Week |
 Cyclacel Pharmaceuticals (NASDAQ: CYCC) [Micro-Cap Biotech/Device] | Cyclacel is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Three orally-available Cyclacel drugs are in clinical development. >>> Video Profile | Cyclacel completes previously announced private placement Cyclacel to present at BIO Investor Forum |
 Cytomedix, Inc. (AMEX: GTF) [Micro-Cap Biotech/Device] | Cytomedix, Inc. is a biotechnology company specializing in the development, production, licensing, and distribution of autologous cellular therapies. It has a broad portfolio of patents in multiple areas. Autologous therapies use a patient's own body products. | Cytomedix Receives ISO 13485 and Canadian Medical Device Certifications Cytomedix to Present AutoloGel System Data at the Desert Foot Conference 2010 |
 Cytori Therapeutics (NASDAQ: CYTX) [Micro-Cap Biotech/Device] | Cytori Therapeutics, Inc. engages in the development, manufacture, and sale of medical technologies to enable the practice of regenerative medicine. The company develops its product pipeline for the treatments of cardiovascular disease, spinal disc degeneration, gastrointestinal disorders, liver and renal disease, and pelvic health conditions >>> Video Profile | Cytori Extends Distribution Agreement with GE Healthcare; Key Focus on Research Market
Cytori Therapeutics Announces Fall 2010 U.S. Conference Schedule |
 CytoSorbents Corporation (OTCBB: CTSO) [Micro-Cap Biotech/Device] | CytoSorbents is a critical-care focused therapeutic device company in clinical trials with CytoSorb™, a state-of-the-art cytokine filter designed to reduce cytokine storm that leads to severe inflammation, multi-organ failure and death in sepsis, burn injury, trauma, ARDS and other life-threatening conditions. >>> Video Profile | CytoSorbents Corporation Awarded $488,958 Grant from the Federal Qualifying Therapeutic Discovery Project Program CytoSorbents Corporation Reports Third Quarter 2010 Financial Results |
 Dance Pharmaceuticals (Private) [Private Biotech/Device] | See below | |
 DataPhysics Research Inc. (Private) [Private Biotech/Device] | DataPhysics Research (DPR) has developed unique software that dramatically reduces data analysis, diagnosis generation and reporting times in both MRI & CT exams. With a 40 to 45 percent time reduction in completing an exam, DPR's platform offered as a Software as a Service model will significantly lower exam costs, achieve maximum reimbursements and provide a higher level of service to the patients >>> Video Profile | DataPhysics Research Rides to the Rescue of Radiologists DataPhysics Research Aims to Streamline Workflow Process for Busy Radiologists |
 DATATRAK International (OTC: DATA.PK) [Micro-Cap Biotech/Device] | For more than a decade, DATATRAK has been a pioneer in the Electronic Data Capture industry. At DATATRAK, we do more than provide software on demand. We are a worldwide application solution provider, offering multi-component eClinical solutions and related services for the entire clinical trials industry. >>> Video Profile | DATATRAK Congratulates Cosmo Pharmaceuticals on Budesonide MMX® Results
DATATRAK International, Inc. Announces Third Quarter Results for 2010 |
 Del Mar Pharmacuticals (Private) [Private Biotech/Device] | Del Mar Pharmaceuticals' mission is to build shareholder value by rapidly developing and commercializing proven anti-cancer therapies in orphan indications where patients have failed modern biologic therapy. | Del Mar Pharma Bets on Glioblastoma Salvage Therapy |
 diaDexus (OTC Bulletin Board: DDXS) [Micro-Cap Biotech/Device] | diaDexus, Inc., is a diagnostics company focused on the development and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease >>> Video Profile | diaDexus Announces Name Change from VaxGen Vaxgen and diaDexus Complete Merger |
 e-Zassi (Private) [Private Biotech/Device] | e-Zassi is the medical device industry's first subscription-based, integrated online business network, decision support software and technology marketplace. Launched in 2008 the company was spun out from Zassi Medical Evolutions. | e-Zassi.com Announces Capitalization and Commercialization Rating TM Service e-Zassi Software to Offer SEO Service of Med-tech Innovations for its Members |
 ECI Biotech (Private) [Private Biotech/Device] | ECI Biotech, Inc. (ECI) is a premier developer and manufacturer of innovative, patented ExpressDetect sensors for rapid infection determination at the point-of-care (PoC) for professional use, as well as consumer OTC markets. Their infection sensor diagnostics can be incorporated into any medical device or consumer product and will ultimately transform the way pathogens are detected in wound care, women's health, baby care and oral care. | Dr. Mitch Sanders, CEO & Founder of ECI Biotech Chosen as Keynote Speaker for BREW Boston 2010 ECI Biotech is being featured at the youngStartup Ventures Life Science and Healthcare Summit |
 EMKinetics (Private) [Private Biotech/Device] | Clinical-stage, medical device company developing neuromodulation technology | Market for Incontinence Products, Therapies Expected to Grow |
 Enox Biopharma, Inc (Private) [Private Biotech/Device] | Enox Biopharma Inc. is an emerging biotechnology company focused on the development and commercialization of advanced Nitric Oxide (NO) technologies for a variety of medical uses. Nitric Oxide is a lipophilic gas, with an exceptionally short molecular half-life, involved in the regulation of diverse physiological mechanisms. | ENOX BIOPHARMA, INC. ANNOUNCES PUBLICATION OF SCIENTIFIC DISCOVERIES Enox Biopharma Will Present its Unique Self-Sterilizing Urinary Catheter at the 49th Annual ICAAC Meeting. |
 EpiCept Corporation (Nasdaq: EPCT) [Micro-Cap Biotech/Device] | EpiCept is a specialty pharmaceutical company that focuses on fulfilling unmet medical needs in cancer treatment and pain management. >>> Video Profile | EpiCept Corporation to Present at the Rodman & Renshaw 12th Annual Global Investment Conference EpiCept Corporation Reports Second Quarter 2010 Operating and Financial Results |
 Functional Nutriments (Private) [Private Biotech/Device] | Functional Nutriments is developing a chemosensitizer and radiosensitizer cancer therapeutic using bioavailable apoptogens. | Dog Cancer Supplement Company Wins 2008 Hawaii Entrepreneur Investor Pitch Competition Functional Nutriments Awarded Federal Grant to Apply its Dog Cancer Nutraceutical Research to Human Cancer |
 GlySure (Private) [Private Biotech/Device] | GlySure has developed a continuous glucose monitoring system using an intravascular, optical fluorescence-based sensor to support clinical implementation of Tight Glycemic Control and Intensive Insulin Therapy. | GlySure presents results of first human ICU testing at Healthios Exchange 2010 Healthcare Investment Conference on Sept 30th |
 Gynesonics (Private) [Private Biotech/Device] | Womens Health. Radiofrequency-Based Therapy, Uterine Fibroids. Gynesonics is a medical device company that focuses on actualizing technological products for women's health. Currently the company is developing a minimally invasive therapeutic apparatus for the treatment of uterine fibroids | |
 HealthLink Europe (Private) [Private Biotech/Device] | HealthLink Europe is an ISO 13485 certified Medical Device Distribution Company with facilities in The Netherlands and The United States. HealthLink's mission is to provide our Medical Device customers with the expertise, service and value necessary to accelerate their growth in Europe, while functioning as a transparent extension of their business. >>> Video Profile | 18th Annual Device Conference, European Commercialization - June 2010 CEOs to share strategies and successes in going public and launching medtech products in Europe HealthLink Europe to Present a Hybrid Sales Model For Successful Device Launches In Europe |
 Heat Biologics (private: private) [Micro-Cap Biotech/Device] | Heat Biologics (Heat) is a clinical-stage company focused on the development and commercialization of two complementary technology platforms that can work alone or together to treat a variety of cancers, viral and autoimmune diseases. Heat's HeatShock technology offers a novel approach to treating cancer and other diseases by using live, modified cell lines to activate the immune system (IS) against specific defined targets. | Heat Biologics Announces Scientific Advisory Board
NIH Awards Grant to Advance Testing of Heat Biologics' Immunotherapy Vaccine to Treat HIV |
 Heilongjiang Tianyi Pharmaceutical Co., Ltd (Private) [Private Biotech/Device] | Heilongjiang Tianyi Pharmaceutical has seven sales regions and 44 main distribution channels. Mainly uses third party trading companies and sales agents. Products are sold to 31 provinces, cities and autonomous regions. Coverage rate up to 32.14% of 2nd tier and above of hospitals in Daqing | |
 Helsinn Healthcare S.A. (Private) [Private Biotech/Device] | Helsinn is a privately owned pharmaceutical group with headquarters in Lugano, Switzerland and premises in Ireland and USA. The Helsinn Group has been built on the basis of a unique business model, focused on the in- and out-licensing of pharmaceuticals and medical devices in therapeutic niche areas. | Palonosetron More Effective Than Granisetron in Controlling Nausea According to The Protest Study Helsinn Announces the Official Opening of it's New R&D Centre of Excellence in Dublin |
 ImmunoCellular Therapeutics (OTC: IMUC.OB) [Micro-Cap Biotech/Device] | IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. >>> Video Profile | ImmunoCellular Therapeutics Receives $244,479 Grant Under the Patent Protection and Affordable Care Program ImmunoCellular Therapeutics Optimizes New Manufacturing Method for Novel Cancer Vaccine |
 Immunome, Inc. (Private) [Private Biotech/Device] | Immunome is a discovery stage biopharmaceutical company that has created a proprietary Native Human Monoclonal Antibody (N-huMAB) platform. N-huMAbs are in the exact structures created by nature and possess the natural safety and protective power of the human immune system. | Immunome Named a Top Innovator Winner |
 IntelGenx Corp. (OB: IGX) [Micro-Cap Biotech/Device] | IntelGenx are a unique drug delivery company focused on improving existing medications by incorporating our proprietary, advanced controlled-release technologies. They are currently developing products for multiple indications including for the treatment of severe depression, osteoarthritis, hypertension, erectile dysfunction and pain management. >>> Video Profile | IntelGenx Acquires Full Ownership and Exclusive Rights to MS Induced Pain Product
IntelGenx Reports Third Quarter 2010 Results and Highlights Recent Developments |
 Intellectual Ventures (Private) [Private Biotech/Device] | Intellectual Ventures' goal is to assemble a world-class team to invent and invest in inventions. Their team is a very unique mix of scientists, technologists, business leaders, strategists, engineers, mathematicians, programmers, attorneys, IP experts, and support staff. | University of Ottawa and Intellectual Ventures Master License Agreement
University of Manitoba and Intellectual Ventures Master License Agreement |
 IntelleWave (Private) [Private Biotech/Device] | Intellewave is a non-invasive, fully automated computer-based system that provides Heart Rate Variability (HRV) analysis for quantitative assessment of the Autonomic Nervous System. >>> Video Profile | IntelleWave Seeks to Improve Patient Care Through Cardiac Analysis |
 Interface Biologics, Inc. (Private) [Private Biotech/Device] | Interface Biologics is a privately held commercial stage company that develops transformative biomedical polymer technology to improve the safety and effectiveness of medical devices. | Interface Biologics - Fresenius Medical Care Sign License Agreement U of T is helping to create a culture of innovation |
 Ion Channel Innovations (Private) [Private Biotech/Device] | Ion Channel Innovations is a development stage biotechnology company formed to develop Ion Channel Therapy (ICT), an innovative gene transfer solution expected to be safe and effective for the long-term treatment of erectile dysfunction (ED), urinary incontinence (UI, urinary urgency, frequency and incontinence related to overactive bladder (OAB)), and potentially other smooth muscle diseases. | |
 IRIDEX Corporation (Nasdaq: IRIX) [Micro-Cap Biotech/Device] | IRIDEX develops, manufactures and markets semiconductor-based laser systems used to treat eye diseases in ophthalmology and skin conditions in dermatology. >>> Video Profile | IRIDEX Reports Improved Third Quarter 2010 Financial Results IRIDEX Announces Commercial Availability of New Adjustable & Intuitive EndoProbe(R) Device for Eye Surgery |
 IsoRay Products (AMEX: ISR) [Micro-Cap Biotech/Device] | IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is the sole producer of the Cesium-131 brachytherapy seed, used to treat prostate and other cancers. The Cesium-131 seed offers a significantly shorter half-life than the two other isotopes commonly used for brachytherapy, which results in a substantially faster delivery of therapeutic radiation, lower probability of cancer cell survival and reduction of the longevity of common brachytherapy side effects. | IsoRay, Inc. Announces Financing Commitment of $4,325,000 IsoRay Awarded More Than $526,000 in Federal Grants for Breast, Brain and Lung Cancer |
 Jan Medical (Private) [Private Biotech/Device] | Using passive sonar techniques with powerful signal processing, detect, identify and locate each type of stroke and brain trauma using a simple headset and portable laptop based console. The system allows continuous monitoring but can make the first diagnosis within 30 heartbeats. |
|
 JenaValve Technology, GmbH (Private) [Private Biotech/Device] | JenaValve Technology is a medical device company specialized in developing transcatheter valve implantation systems. The company has designed TAVI two systems, one for the transapical (TA) approach and one for the transfemoral (TF) approach. | JenaValve Technology Reports Nine Successful Human Implantations
of its Transapical TAVI System |
 KC BioMedix (Private) [Private Biotech/Device] | KC BioMedix specializes in the care and treatment of infants born prematurely. The company offers a proprietary neurostimulation device that accelerates a premature infant's transition from tube to bottle feeding. It reduces the length of stay in the Neonatal ICU, saving up to $3,500/day. | KCBioMedix® Announces Appointment of John C. Kraczkowsky as New President and CEO Dr. Steven Barlow Earns Higuchi-KU Endowment Research Award |
 Kenta Biotech AG (Private) [Private Biotech/Device] | Kenta Biotech is focusing on the discovery and development of innovative, fully human monoclonal antibodies for the life-saving treatment of patients with serious infectious diseases. | Kenta Biotech reports 100% survival with panobacumab in life-threatening hospital-acquired pneumonia Kenta Biotech Announces Collaboration with Rentschler Biotechnologie for Antibody Development |
 LifeSpine (Private) [Private Biotech/Device] | Life Spine is a developer, manufacturer and marketer of specialized, proprietary medical devices serving the orthopaedic and neurosurgery communities. This is a unique business concept that allows the world's leading surgeons to utilize Life Spine to customize, design, develop and patent new instrumentation and techniques to achieve better patient outcomes. | Life Spine announces completion of surgeries utilizing OCTAVE™ Posterior Fusion System Life Spine announces FDA clearance of DYNA-LINK® Spinal System and PRESIDIO™ Spinal Plating System |
 LoneStar Heart (Private) [Private Biotech/Device] | LoneStar Heart, Inc. is a Texas and California based biomedical company developing new therapies to preserve and restore adequate heart function in patients with Congestive Heart Failure (CHF). >>> Video Profile | CardioPolymers Continues Development on Heart Failure Device
CardioPolymers, Inc. completed a merger with LoneStar Heart, Inc |
 MacuCLEAR Inc. (Private) [Private Biotech/Device] | MacuCLEAR Inc. is a specialty clinical-stage pharmaceutical company focused on developing and commercializing novel solutions for vascular disorders of the eye. It’s first target is Age Related Macular Degeneration, (AMD), the leading cause of blindness for people over 50 years of age, affecting 30 million people worldwide, representing a >$5Billion market, for which there is currently no approved treatment for 90% who have this terrible disease. >>> Video Profile | Dr. Chiou Delivers Keynote Address at APJGC [pdf] MacuCLEAR Rejects HOTI Acquisition [pdf] |
 Medical Image Mining Laboratories (Private) [Private Biotech/Device] | Positioned at the junction of healthcare and technology to make the analysis of medical images more efficient through machine learning. Their Lesion Annotation & Volume Assessment software quantifies the volume of MS lesion on MRIs. Intends to expand to include tumors and brain atrophy measures. | New Method Of Describing Psoriasis Quantifying and Tracking Vitiligo |
 MedicaSafe (Private) [Private Biotech/Device] | MedicaSafe is creating solutions for medication compliance/adherence. The company's drug dispensing devices can assure medication adherence and compliance in either commercial clinical settings or during clinical trials. | |
 MEDomics (Private) [Private Biotech/Device] | MEDomics was founded in July of 2008 with the mission of providing Mutation Expert-based Diagnosis to support the physician in delivering personalized medicine based on the patient genome. | MEDomics Presents Clinical Experience with MitoDx Test for Mitochondrial Diseases at a Major Diagnostics Meeting in Beijing, China
MEDomics Performs The First NEXTGEN Sequencing "Mini Genome" Clinical Test |
 Mercator MedSystems (Private) [Private Biotech/Device] | Mercator MedSystems, Inc. is focused on the treatment of vascular inflammation utilizing its catheter-guided, microfluid injection systems for site-specific, non-systemic delivery of therapeutic agents directly across any blood vessel. | Mercator MedSystems Receives Grant from Department of Treasury - Third Federal Grant this Year Promising New Therapy for Drug-Resistant Hypertension Presented at Interventional Cardiology Meeting in Washington, D.C. |
 Minnow Medical (Private) [Private Biotech/Device] | Minnow Medical, Inc., is a cardiovascular medical device company that has invented a novel platform technology employing radiofrequency thermoplasty (RFT) for the treatment of cardiovascular artery and vein disease | GRT Catheter Featured in May/June 2010 Issue of Diagnostic and Invasive Cardiology
Minnow Medical to Present at the Onemedforum Finance Conference on January 12 |
 Miracor Medical Systems GmbH (Private) [Private Biotech/Device] | Miracor has developed a unique technology platform addressing large unmet clinical needs in acute coronary syndrome, heart failure and cardiac surgery patients.The Company has an experienced management team and Board of Directors with a solid track record to develop and commercialize advanced medical devices in cardiology and cardiac surgery. | Miracor is granted U.S. patent for its PICSO® Wien Algorithm designed to improve acute coronary syndrome (ACS) revascularization following primary percutaneous coronary intervention (PCI) Miracor is selected as 'Hot Pick of the Month' by Clinica's Medtech Ventures |
 Mobisante, Inc. (Private) [Private Biotech/Device] | Mobisante proposes to democratize ultrasound imaging by bringing to market very low cost mobile point-of-care ultrasound diagnostic systems that are based on smart phones and Internet cloud services. They can be used by doctors, nurse practitioners, and physician extenders to increase the range and accuracy of diagnostic procedures they can perform on their own. | Mobisante secures seed financing from WRF Capital Mobisante wins the Best Mobile Healthcare Device Award at Mobile Health Expo. |
 Nanospectra Biosciences (Private) [Private Biotech/Device] | Nanospectra Biosciences is an emerging life science company primarily focused on the development and commercialization of AuroLase cancer therapy, which is designed to selectively destroy virtually all solid tumors. | Nanospectra Awarded $1.3 Million NCI Grant for Brain Tumor Application Nanospectra Founders Halas and West named Inventors of the Year by State Bar of Texas |
 NanoViricides, Inc. (OTCBB: NNVC.OB) [Micro-Cap Biotech/Device] | NanoViricides, Inc. is working in the general field of Nanomedicine. This is a very diverse field and encompasses a wide range of materials and applications. Specifically, we are working in the area of targeted anti-viral therapeutics. >>> Video Profile | NanoViricides Announces That The Company Has Been Invited To Present at Dengue Research Meeting Sponsored by the National Institutes of Health Interview With Dr. Eugene Seymour Of NanoViricides, Inc. |
 nContact Surgical, Inc. (Private) [Private Biotech/Device] | nContact Surgical is an early stage development company focused on providing new tissue coagulation devices used during surgical procedures. | nContact Raises $16 Million in Equity Financing nContact Advances Leadership Position in the Development of Closed Chest Ablation Techniques |
 NeoChord (Private) [Private Biotech/Device] | Artificial Chordae Tendineae for Mitral Valve Repair >>> Video Profile | Neochord Enrolls First Patient in European Study
NeoChord Hopes To Begin a Human Clinical Trial This Summer |
 NeoGenomics (OTC: NGNM.OB) [Micro-Cap Biotech/Device] | NeoGenomics offers testing in clinical genetics, molecular diagnostics, and flow cytometry. >>> Video Profile | 2010-11-04 NeoGenomics Reports ObamaCare Tax Grant 2010-10-28 NeoGenomics Q3 2010 Earnings Release |
 Neoprobe (OTC: NEOP.OB) [Micro-Cap Biotech/Device] | Neoprobe Corporation is focused on developing and commercializing innovative biomedical products that meet the critical intraoperative, diagnostic and therapeutic treatment needs of patients and physicians. Their primary area of focus is in improving cancer surgery outcomes by using their market-leading gamma detection devices in combination with radiopharmaceutical agents also referred to as "tracing" or "targeting" agents. >>> Video Profile | Neoprobe Hosted Analyst Day In NYC Neoprobe Granted Pre IND Meeting With FDA To Review RIGS Technology |
 NeoStem (AMEX: NBS) [Micro-Cap Biotech/Device] | NeoStem, Inc. is an international biopharmaceutical company with product and service revenues, global research and development capabilities and operations in three distinct business units: (i) U.S. adult stem cells, (ii) China adult stem cells, (iii) China pharmaceuticals. | NeoStem Announces Pricing of Concurrent Offerings for $19 Million in Gross Proceeds NeoStem Provides Third Quarter Update |
 Neovasc (CDNX: NVC.V) [Micro-Cap Biotech/Device] | Neovasc develops, manufactures and markets medical devices for the rapidly growing vascular and surgical marketplace. Neovasc was formed on July 1, 2008 following the acquisition of two Israeli development-stage device companies (Neovasc Medical Ltd. and B-Balloon Ltd) by the Canadian-based Medical Ventures Corporation | 11-9-2010 Neovasc Reports Financial Results for the Third Quarter of 2010 9-27-2010 Neovasc Reducer™ for Refractory Angina Featured in Live Case Session at TCT 2010 Conference NeoVasc's latest press releases |
 NeoVista (Private) [Private Biotech/Device] | NeoVista develops and markets technology designed to treat wet age-related macular degeneration using targeted strontium-90 beta radiation. >>> Video Profile | Good Health article: "Surgeons stuck a needle in my eye and now I can see again"
NeoVista, Inc. Announces the Launch of VIDION® ANV® Therapy System in UK for Treating Wet Age-Related Macular Degeneration |
 Neurotez, Inc. (Private) [Private Biotech/Device] | Neurotez Inc. is a privately held Delaware corporation formed to launch the clinical development of recombinant human Leptin as a hormone replacement therapy for Alzheimer's disease ("AD"), and as a preventative remedy for those at risk. | Neurotez, Inc. Awarded Multi-Million Dollar NIH Grant to Advance a Leptin Product into Clinical Trials for Treating Alzheimer's Disease. |
 New World Laboratories, Inc. (Private) [Private Biotech/Device] | Specializes in the research and development of unique therapeutics and technologies for Regenerative Medicine. | New World Laboratories Forges Ahead with Novel Regenerative Therapeutics |
 NOCIMED (Private) [Private Biotech/Device] | NOCISCAN™ is a non-invasive, pain-free, non-significant risk, objective diagnostic test being developed to diagnose lumbar disc pain based on a derivative of Magnetic Resonant Imaging (MRI) called Magnetic Resonance Spectroscopy (MRS). | Modified Magnetic Resonance Spectroscopy Diagnosis of Painful and Non-Painful Lumbar Intervertebral Discs |
 Novadaq Technologies Inc. (TSX: NDQ) [Micro-Cap Biotech/Device] | Real-time imaging to assess organs, tissues and vessels during surgery >>> Video Profile | Novadaq CEO to Present on SPY Imaging at September Investor Conferences
Novadaq Signs North American Marketing and Sales Agreement with LifeCell |
 Oculus Innovative Sciences (NASDAQ: OCLS) [Micro-Cap Biotech/Device] | Oculus Innovative Sciences is a biopharmaceutical company focused on the development, manufacture and marketing of a family of products intended to help prevent and treat infection in wounds. >>> Video Profile | Oculus Innovative Sciences Launches Microcyn®-Based Dermatology HydroGel in Mexico
Oculus Innovative Sciences to Present at the Rodman & Renshaw 12th Annual Healthcare Conference on September 14 in New York City |
 Oncoscope, Inc. (Private) [Private Biotech/Device] | Cell nucleus size is a primary marker used by pathologists to diagnose pre-cancerous tissue. Oncoscope's optical biopsy device applies angle-resolved low coherence interferometry to light scattered by epithelial tissue in the esophagus to determine the average size of cell nuclei in each depth layer. | |
 Ophthalmic Imaging Systems (OTC: OISI.OB) [Micro-Cap Biotech/Device] | Ophthalmic Imaging Systems is the leading provider of ophthalmic digital imaging and informatics systems. Through its wholly owned subsidiary, Abraxas Medical Solutions, the Company provides informatics software to OB/GYN and orthopedic physicians. >>> Video Profile | Ophthalmic Imaging Systems’ Subsidiary Abraxas Medical Solutions Ranked Among Top 20 Ambulatory EMR Vendors for 2011 by Black Book Rankings
Ophthalmic Imaging Systems’ Abraxas EMR Receives ONC-ATCB 2011/2012 Certification |
 OptiMedica (Private) [Private Biotech/Device] | OptiMedica Corporation has developed and commercialized a pattern-scanning method of photocoagulation used to treat a variety of retinal conditions, such as diabetic retinopathy, age-related macular degeneration, and retinal vascular occlusive disease. >>> Video Profile | OptiMedica's Laser Cataract Surgery System to be Featured in Three Clinical Presentations at ESCRS 2010
OptiMedica Sells Retina And Glaucoma Business To Topcon, Sharpens Focus On Laser Cataract Surgery Market |
 Ortho Kinematics (Private) [Private Biotech/Device] | Ortho Kinematics, Inc. is a spine diagnostics company focused on spine motion analysis products and services.
| Ortho Kinematics Launches Multi-Site Clinical Study of KineGraph VMA™
Ortho Kinematics Raises $3.5 Million and Relocates to Austin, TX |
 Ovatech (Private) [Private Biotech/Device] | Ovatech Inc., based in Auburndale, Mass., is a privately held emerging medical technology company that is focused on products to enhance women's health. In addition to Ovaprene™, there are four additional, important products from the Company's proprietary platform. | Ovatech™ reports successful completion of Phase 2 clinical trial of Ovaprene™ non-hormonal intravaginal contraceptive ring |
 Oxygen Biotherapeutics (NASDAQ: OXBT) [Micro-Cap Biotech/Device] | Oxygen Biotherapeutics is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine. >>> Video Profile | Oxygen Biotherapeutics to Showcase New DERMACYTE(R) Oxygen-Enriched Lotions at Leading Spa and Resort Conference in New York City
Oxygen Biotherapeutics Receives DSMB Approval to Proceed to the Next Cohort in Its Phase II-B Clinical Trial for Traumatic Brain Injury |
 PCAsso Diagnostics LLC (Private) [Private Biotech/Device] | PCAsso is a research and development diagnostics company committed to the identification and development of novel medical diagnostic technologies. They are currently developing PolyChromatic Angiography (PCA) a new diagnostic tool for diseases of the retina that they expect to be a "best-in-class"/ "next generation" product. | PCAsso Diagnostics Wins Most Innovative Technology Award
Columbia University Licenses Retinal Imaging Technology to PCAsso Diagnostics |
 PDS Biotechnology Corporation (Private) [Private Biotech/Device] | PDS Biotechnology Corporation (PDS) is commercializing a new generation of safer and more potent nanotechnology-based therapies to treat cancer and infectious diseases. PDS owns VersamuneTM, a platform nanotechnology that has demonstrated eradication and prevention of aggressive cancers and pathogenic diseases with single low doses of the VersamuneTM-based products | PDS Biotechnology Corporation Awarded $1.28M National Cancer Institute Contract PDS Biotechnology and UNC awarded NIH grant to develop novel nanocrystal technology |
 PearlDiver (Private) [Private Biotech/Device] | PearlDiver Technologies, Inc. is a life sciences information, data and research firm. PearlDiver's engineers and analysts aggregate, process and then organize existing databases of patient, reimbursement, claims and clinical data into products for manufacturers, hospitals, patients, insurance companies and others. >>> Video Profile | |
 Pico-Tesla Magnetic Therapies, Inc. (Private) [Private Biotech/Device] | Pico-Tesla Magnetic Therapies is an emerging medical technology company focused initially on Parkinsons Disease. >>> Video Profile | Pico-Tesla expands operations to Midwest region
Pico-Tesla's Magneceutical™ Therapy featured in this August's EP Lab Digest |
 Pressure BioSciences, Inc. (Nasdaq: PBIO) [Micro-Cap Biotech/Device] | Pressure Biosciences INC. is a life sciences company focused on the development and commercialization of a novel, enabling, platform technology called pressure cycling technology ("PCT"). >>> Video Profile | Pressure BioSciences, Inc. to Collaborate With the Lawrence Berkeley National Laboratory on the Analysis of Microorganisms in Oil Spills: Results Could Lead to Improved Strategies for Environmentally-Safe Clean-up
Pressure BioSciences, Inc. Announces Initial Equity Research Coverage by Zacks Investment Research |
 Provectus Pharmaceuticals (OBB: PVCT) [Micro-Cap Biotech/Device] | Provectus Pharmaceuticals, Inc. develops, licenses and markets, and plans to sell products in three sectors of the healthcare industry, such as Over-the-counter (OTC) products, Prescription drugs and Medical device systems. |
Provectus Pharmaceuticals, Inc. Announces $1 Million Investment by Lincoln Park Capital Fund, LLC Provectus Pharmaceuticals Initiates Phase 2c Clinical Trial of PH-10 for Psoriasis |
 QR Pharma, Inc (Private) [Private Biotech/Device] | The company has two compounds in clinical development, both with disease modifying activities, e.g. they have the potential to stop the progression of the disease as well as symptomatic efficacy. | QR Pharma receives FDA clearance to conduct clinical trials with its second novel Alzheimer compound, Bisnorcymserine QR Pharma's Posiphen® was shown in a Clinical Mechanism of Action Study to Enter the Brain and to Inhibit Amyloid Precursor Protein |
 QuantumCor (Private) [Private Biotech/Device] | QuantumCor is a medical device company developing Transcatheter Mitral Valve Repair (TMVR) technologies to allow a dilated mitral valve to be repaired in a minimally invasive cardiac cath lab procedure for the treatment of mitral regurgitation. >>> Video Profile | QuantumCor's "Transcatheter Mitral Valve Repair" uses a well understood and commonly used cardiac cath lab procedure to access the mitral valve annulus. |
 Regenicin (OTC: RGIN.OB.OB) [Micro-Cap Biotech/Device] | Regenicin, Inc., is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs. Regenicin is playing a critical role in the development of the therapeutic candidate, PermaDermA, a technology that uses the patient's own skin cells to generate living, tissue-engineered skin for the treatment of severe burns. >>> Video Profile | Regenicin, Inc. Receives Central Contractor Registration (CCR) Department of Defense Provides Funding to Lonza to Move Therapeutic Candidate PermaDerm™ into the First Clinical Trials for Adults |
 RepRegen Ltd (Private) [Private Biotech/Device] | RepRegen is an emerging medical device company using patent-pending repair and regeneration technology in two platforms designed to mend and regrow tissue in vivo. The first platform is focused on bone and other (hard) tissue, whereas the second platform is focused on muscle and other (soft) tissue. | RepRegen™ receives CE marking approval for StronBone™
RepRegen™ reports data from an in vivo study of StronBone™ |
 Rothman Healthcare (Private) [Private Biotech/Device] | Rothman Healthcare Corporation (RHC) leverages electronic health record data to evaluate and visualize patient condition. Their tool, the Patient Condition Tracker (PCT), analyzes, synthesizes, and graphically displays a real-time, individual patient score of health, enabling hospitals and nurses to prioritize and respond rapidly to changes in patient condition and improve outcomes. | HIStalk Interviews Co-founder Michael Rothman Rothman Healtchare announces partnership with Blessing Health System |
 Salient Pharmaceuticals (Private) [Private Biotech/Device] | Formed in 2007, Salient Pharmaceuticals mission is to improve health and quality of life while strengthening the odds of therapy success for patients who suffer from the debilitating effects of chronic and/or acute diarrhea. | Salient Enrolls First Patients in New Cancer Therapy-Induced Study in Canines Salient Pharmaceuticals Meets Goals on Second Round Funding from Texas Emerging Technology Fund |
 SEA Medical Systems, Inc. (Private) [Private Biotech/Device] | S.E.A. Medical Systems, Inc. is a private medical device company pioneering real-time advanced fluid sensing with smart solutions for safe preparation and delivery of IV medications. >>> Video Profile | S.E.A. Medical Systems, Inc. Presents Developments in Washington D.C. on October 20, 2010
S.E.A. Medical Developing Next Generation Prototype for IV Error Prevention |
 Senesco Technologies (AMEX: SNT) [Micro-Cap Biotech/Device] | Senesco Technologies is a U.S. biotechnology company, developing its proprietary eiF5A ("Factor 5A") gene technology as a potential treatment for both oncology and inflammatory conditions. >>> Video Profile | Senesco Technologies Awarded Funding Under Tthe U.S. Patient Protection And Affordable Care Act Senesco Technologies Regains NYSE AMEX Listing Compliance |
 Sernova Corp. (TSX:V: SVA.V) [Micro-Cap Biotech/Device] | Sernova Corp is a medical device and therapeutic company in the cell therapy field with a first product focus on diabetes. Sernova's platform technologies include the Cell Pouch, a novel, proprietary, polymer device for implantation and long-term survival of therapeutic cells, and Sertolin, which provides local protection of therapeutic cells from the immune system. | Prominent Transplant Surgeon, Dr. Steven Paraskevas, Joins Sernova Scientific Advisory Board Sernova Now Has Financial Resources to Start Clinical Trials in 2011 |
 Signal Genetics/Myeloma Health LLC (Private) [Private Biotech/Device] | Myeloma Health is a privately held predictive genetic testing company focused on oncology. The goal of Myeloma Health is to provide cancer patients with their correlated predictive outcome of disease type and odds of relapse, and guide physicians to the optimal treatment regimen based on their specific genetic expression profile. | Genomics Researchers Have a Bone to Pick with Multiple Myeloma |
 Sound Surgical Technologies LLC (Private) [Private Biotech/Device] | Sound Surgical Technologies LLC (SST), creator of the VASER® Lipo System, focuses on ultrasonic technologies and related techniques for aesthetic surgery. | Sound Surgical Technologies Introduces VASER® shape MC1™
The New Face of Body Contouring Not Only Reshapes But Recycles |
 Spherix Incorporated (Nasdaq: SPEX) [Micro-Cap Biotech/Device] | Spherix Incorporated is developing innovative biopharmaceutical products and providing technical and regulatory consulting services to food, consumer products and pharmaceutical companies. >>> Video Profile | Windhover Information Names D-Tagatose One of Top 10 Most Promising CV/Metabolic Drugs in Development
Spherix Announces Second Quarter 2010 Financial Results |
 SpineSmith Partners, LLC (N/A: N/A) [Micro-Cap Biotech/Device] | SpineSmith designs, develops and markets implants and biologics for surgical fixation, correction and tissue regeneration of the spine. They take a different approach from other companies, utilizing a collaborative process between engineers and spine surgeons. | SpineSmith Partners Announces FDA Clearance and Product Launch of VisuALIF Interbody Fusion Device SpineSmith Hires New VP of Research and Development |
 STENTYS (EuroNext Paris: STNT.PA) [Micro-Cap Biotech/Device] | STENTYS offers simple, innovative solutions to interventional cardiologists when treating the challenging disease of their patients. When dealing with acute myocardial infarction or coronary artery disease close to a side branch, the STENTYS platform provides an efficient and elegant new treatment approach that does not demand any specific training and assures long term clinical results for patients. >>> Video Profile | STENTYS appoints Mr Michel Darnaud to its Board of Directors STENTYS self-apposing stent proves superior to conventional treatment of Acute Myocardial Infarction |
 Synergetics USA (Nasdaq: SURG) [Micro-Cap Biotech/Device] | Synergetics USA, Inc. designs, manufactures and markets medical devices for use primarily in ophthalmic surgery and neurosurgery and for other healthcare applications. The company was formed in the September 2005 merger of Valley Forge Scientific Corp. and Synergetics, Inc. | Synergetics Reports Increases In Third Quarter Sales And Net Income |
 T-Ray Science, Inc (TSX-V: THZ) [Micro-Cap Biotech/Device] | Company: Company: T-Ray Science, Inc.
Brief_Description: T-Ray Science, Inc. is focused on the commercialization of a novel skin cancer imaging device developed by the BC Cancer Agency, which has been tested on about 1000 lesions at Vancouver General Hospital. | T-Ray Science, Inc. Approved for BC Tax Credit Program T-Ray Science, Inc. Licenses Lung Cancer Detection Technology From The BC Cancer Agency |
 Telcare (Private) [Private Biotech/Device] | Telcare has developed cellular machine-2-machine technology to bridge the gap between home glucose monitoring patients and their caregivers in order to improve the daily care of their diabetes. | TELCARE, INC., Exhibits First Cellular-Enabled Glucose Meter at Joint Meeting of FDA and FCC
Telcare Phones in $2.5M |
 Telik, Inc. (NASDAQ: TELK) [Micro-Cap Biotech/Device] | Telik, Inc.is a biopharmaceutical company dedicated to discovering, developing and commercializing novel small molecule drugs to treat cancer and other serious diseases. >>> Video Profile | TELIK Announces Second Quarter 2010 Financial Results
TELIK Announces Publication of Review Focused on the Inhibition of the Enzyme GSTP1-1 as a Target for a New Cancer Treatment |
 Threshold Pharmaceuticals (NASDAQ: THLD) [Micro-Cap Biotech/Device] | Threshold is a biotechnology company focused on the discovery and development of therapeutics based on Tumor Hypoxia, a powerful scientific platform that offers broad potential to treat most solid tumors. | Threshold Pharmaceuticals Announces Promising Early Phase 1 Clinical Trial Results in Patients With Advanced Leukemias Follow-up Data From Threshold Pharmaceuticals' Phase 1/2 Clinical Trials of TH-302 Demonstrate Broad Activity in All Combinations Against Multiple Tumor Types |
 Tianyin Pharmaceutical Co., Inc (NYSE: TPI) [Micro-Cap Biotech/Device] | Tianyin Pharmaceutical Co., Inc., headquartered in Chengdu, Sichuan Province of China, is a leading manufacturer and supplier engaged in the development, manufacturing, marketing and sale of modernized traditional Chinese medicines and branded generics, with two state-of-the-art manufacturing facilities and an extensive nationwide sales and distribution network throughout China. >>> Video Profile | Top 4 Stocks In The Drug Manufacturers-Other Industry With The Highest Dividend Yield (TPI, RELV, TEVA, NVO) Tianyin's Dr. James Jiayuan Tong is Invited to Speak at the CFO China Summit 2011 on January 19, 2011 at the St. Regis Hotel, Beijing |
 Tibion Bionic Technologies (Private) [Private Biotech/Device] | Tibion is a privately held company designing and developing bionic medical devices and therapies that address the needs of mobility impaired patients. The company's products are intended for the treatment of various musculoskeletal and neuromuscular deficiencies. | Tibion Bionic Leg Wins Medical Design Excellence Award Bionic Leg at Whittier: Stroke Patients Walk Their Way to Gait Recovery |
 Tolera Therapeutics (Private) [Private Biotech/Device] | Tolera offers a highly specific T-cell antagonist monoclonal antibody technology (anti-TCR) with broad application potential in T-cell mediated disease such as transplant rejection, autoimmune disease (e.g. type 1 diabetes) and hematological malignancies (e.g. pediatric ALL). | Tolera Therapeutics granted Orphan Drug Designation for treatment of Type 1 diabetes mellitus Tolera Therapeutics Honored as One of the 2010 "Michigan 50 Companies to Watch" |
 TONIX Pharmaceuticals, Inc. (Private) [Private Biotech/Device] | TONIX Pharmaceuticals is developing high-value prescription therapeutics for chronic Central Nervous System (CNS) conditions, such as Fibromyalgia Syndrome and Post-Traumatic Stress Disorder. Our two lead products are based on cyclobenzaprine, which is FDA approved at higher doses for an unrelated condition. TONIX's new formulations of cyclobenzaprine are optimized for bedtime use and provide clear value to patients and third-party payers. | TONIX Pharmaceuticals Reports Analysis of Phase 2a Study of Very Low Dosage Cyclobenzaprine in Fibromyalgia Syndrome (FMS)
TONIX Pharmaceuticals Elects Ernest Mario, PhD, to its Board of Directors |
 Velomedix (Private) [Private Biotech/Device] | Therapeutic hypothermia devices for patients patients suffering from ischemic and reperfusion injury effects of cardiac arrest, heart attack, stroke and traumatic brain injury. | Giving the Cold Shoulder to Cardiac Arrest Complications
|
 Vyteris, Inc. (OTC BB: VYTR.OB.OB) [Micro-Cap Biotech/Device] | Vyteris Inc is the developer of the first active drug delivery patch to receive marketing clearance from the U.S. Food and Drug Administration. It's proprietary active transdermal drug delivery (iontophoresis) technology, smart patch, delivers drugs comfortably through the skin using low-level electrical energy. >>> Video Profile | Vyteris Announces Definitive Agreement to Merge With MediSync BioServices
Vyteris and Georgia Tech Enter Into Exclusive Agreement for Transdermal Drug Delivery Technologies |
 Wafergen Biosystems (OTC: WGBS.OB) [Micro-Cap Biotech/Device] | Wafergen develops, manufactures and sells state-of-the-art systems for genetic analysis for the life science and pharmaceutical industries. >>> Video Profile | WaferGen Expands Scientific Advisory Board with Appointment of Industry Leader Dr. Timothy J. Triche WaferGen Announces USC Purchases SmartChip System to Expedite Development of Cancer Therapy Through More Effective Biomarker Profiling |
 Wave 80 Biosciences (n/a: n/a) [Micro-Cap Biotech/Device] | Wave 80 Biosciences develops next-generation molecular diagnostic instruments and consumables for hepatitis C, hepatitis B, HIV/AIDS, and other human health conditions. Distinguished by a novel one patient-one test usage model, best-in-class performance, and a superior value proposition. | Wave 80 awarded $7.5 million NIH contract for HIV rapid virus testing Wave 80 chief executive to address microsystems commercialization conference in Chongqing, China |
 Wound Management Technologies, Inc (OB: WNDM) [Micro-Cap Biotech/Device] | Wound Management Technologies, Inc. (WNDM) is a rapidly growing provider of advanced biotech medical devices. Our lead product, CellerateRX® , is a unique, patented activated collagen that addresses the expanding diabetes and greater wound care markets. The company is also developing a resorbable bone wax and bone void filler product line. >>> Video Profile | CellerateRX® Effectively Manages Diabetic Ulcers…New CDC Report Indicates Type 2 Diabetes on the Rise… Diabetes Projected to affect up to 1 in 3 Americans by 2050 All-Time High in Q Orders for Wound Management Technologies, Inc. |
 ZS Pharma Inc. (Private) [Private Biotech/Device] | ZS Pharma, Inc. is a privately held specialty pharmaceutical company located in Ft. Worth, TX and focused on the development and commercialization of proprietary oral sorbent technology. Their compound, known as Zirconium Silicate (ZrSi), selectively removes life-threatening toxins in patients suffering from kidney and liver disease and related conditions. | Developing a Breakthrough in Hyperkalemia Treatment Hyperkalemia: Addressing a Significant and Poorly Met Healthcare Need |
Presenting Companies from Past OneMedForums
• NY June 2010 / SF Jan 2010
• Presenting Company Benefits (PDF)